<DOC>
	<DOCNO>NCT02107014</DOCNO>
	<brief_summary>We find low dose naltrexone ( LDN ) substantially reduce pain associate fibromyalgia syndrome . We believe LDN may work via novel anti-inflammatory channel . The purpose study determine LDN lower inflammatory marker individual fibromyalgia .</brief_summary>
	<brief_title>Low Dose Naltrexone ( LDN ) Immune Monitoring</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Females age 1865 Meets criterion 1990 ACR criterion fibromyalgia Able receive venous blood draw twice week 16 week Sufficient symptom variability baseline report Patient complete daily report 2 week baseline period least 80 % completion rate . Opioid use Significant psychological comorbidity discretion investigator compromise study integrity Location prohibit travel Stanford Blood clot disorder Rheumatologic autoimmune disease Acute infection Baseline blood ESR &gt; 60 , CRP great 3.0mg/L , positive rheumatoid factor , positive ANA Use blood thin medication Pregnant currently plan become pregnant Current use aspirin , ibuprofen , naproxen , confoundingantiinflammatory medication part regular medication regimen . Known allergy Naltrexone Naloxone Currently participate another treatmentbased research study Selfreported inability refrain alcohol duration study period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>